• TMB as New Biomarker in NSCLC - Ready for Clinic?

    7 monthes ago - By Medscape

    A new biomarker - high tumor mutational burden - identifies lung cancer patients who do better on immunotherapy than on chemotherapy.
    Medscape Medical News
    Read more ...